← Back to all trials
Completed
NCT04158648
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
Conditions: Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A
Sex: All
Healthy volunteers: No
Phase: PHASE3
Enrollment: 73
Sponsor: Hoffmann-La Roche
Location: Childrens Hospital LA Los Angeles California
Summary
This is a multicenter, open-label, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab in participants with mild or moderate hemophilia A without inhibitors against factor VIII (FVIII).
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of mild (FVIII level between \>5% and \
Source: ClinicalTrials.gov (NCT04158648). StuddyBuddy aggregates publicly available trial information.
